• Users Online: 422
  • Print this page
  • Email this page
REAL WORLD DATA
Year : 2019  |  Volume : 2  |  Issue : 1  |  Page : 112-118

Dermatofibrosarcoma protuberans of head and neck: Clinical outcome of nine cases treated with imatinib


1 Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
2 Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India
3 Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India

Correspondence Address:
Vanita Noronha
Department of Medical Oncology, Tata Memorial Hospital, Room 304, Homi Bhabha Block, Parel, Mumbai - 400 012, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/CRST.CRST_36_19

Get Permissions

Background: Dermatofibrosarcoma protuberans (DFSP) of head and neck is rare and presents a unique challenge as surgery may be associated with poor cosmetic and functional outcomes or inadequate surgical margins. There is a paucity of data regarding the use and effectiveness of imatinib in head and neck DFSP. We retrospectively analyzed head and neck DFSP cases treated with imatinib. Patients and Methods: Data of nine head and neck DFSP cases treated with imatinib were retrieved from our hospital electronic medical records. Demographic and toxicity data were presented using descriptive statistics and simple percentages; survival was calculated using the Kaplan–Meier method. Results: The median age was 40 years (range, 22–47 years) with almost equal male to female distribution. The site of primary tumor was scalp in seven patients, face and neck in one patient each. One-third of the patients had metastatic disease; sites of metastases included lung, lymph node, soft tissue, and brain. Fibrosarcomatous variant was present in four patients. Eight patients underwent wide local excision for the primary tumor. Three patients each received imatinib in the neoadjuvant, adjuvant, and palliative setting. The response rate to imatinib in the neoadjuvant and palliative setting was 66.7% and 33.3%, respectively. Four patients received adjuvant radiotherapy (RT) after surgery for recurrent disease and one patient received palliative hemostatic RT to the local site. The median duration of follow-up was 84 months (range, 2–148 months), and median recurrence free survival was 82 months (interquartile range, 74–83 months). All patients were alive until last follow-up. Conclusions: Head and neck DFSP requires multimodality management with incorporation of neoadjuvant imatinib and adjuvant RT to achieve favorable clinical outcomes.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed159    
    Printed20    
    Emailed0    
    PDF Downloaded27    
    Comments [Add]    

Recommend this journal